Closed Loop Therapies BV (CLT), an emerging medical company that develops a novel treatment for artial fibrillation, won second place in the final of the Eurecan European Venture Contest (EEVC) 2010 in Barcelona. CLT was presented by Dr. Dan Gelvan, Cofounder and Supervising Director.

 

The 2010 edition of EEVC involved 15 locations across Europe in Austria, Belgium, Denmark, France, Germany, Italy, Luxembourg, Poland, Hungary, Spain and the UK. A total of 987 companies from 24 countries participated in the contest, out of which 449 ICT, Cleantech and Healthcare companies were selected by experts to present at one of the 15 qualifying events across Europe. CLT participated in the Benelux Venture Forum event in Luxembourg in November and was selected to the top10 who proceeded to the semifinal at EVS European Venture Summit in Düsseldorf in December. From 150 companies at EVS, CLT was selected to the top 25 to participate in the final in Barcelona.

​

Closed Loop Therapies (CLT) BV was established in 2009 as a joint venture between the Erasmus Medical Centre (Rotterdam, the Netherlands), one of the most prominent medical institutes in Europe, and CLT Israel. The object of this joint venture is to develop and commercialise a novel fully implantable therapeutic device, consisting of an arrhythmia detection- and pacing module and a medicine pump, designed to provide automatic and immediate treatment of emerging atrial fibrillation (AF).